3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
3
Thoracic
2
Head & Neck
1
Gastrointestinal
1
Conditions
Thyroid Neoplasms
1
Pancreatic Neoplasms
1
Melanoma
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
pembrolizumab
66
Cisplatin
55
Radiotherapy, Intensity-Modulated
28
Carboplatin
27
Nivolumab
26
Paclitaxel
21
Magnetic Resonance Spectroscopy
21
Radiotherapy
20
Cetuximab
16
Specimen Handling
15
Docetaxel
15
Radiation
14
Gemcitabine
13
Fluorouracil
12
Biopsy
12
durvalumab
11
Platinum
11
Taxes
10
Surveys and Questionnaires
10
Drug Therapy
10
1,2-diaminocyclohexaneplatinum II citrate
10
Capecitabine
9
trametinib
8
tislelizumab
6
lenvatinib
6
dabrafenib
6
cemiplimab
6
atezolizumab
6
Radiosurgery
6
Ipilimumab
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
naporafenib
×
Head & Neck
×
Clear all
NCT05907304
2026-02-27
SEACRAFT-1
Erasca, Inc.
Phase 1
Active not recruiting
86 enrolled